AMENDMENTS TO THE CLAIMS

1-66. (Canceled)

67. (New) A parenteral vaccine formulation comprising:

(a) at least one immunogenic substance selected from the group consisting of an antigen, an allergen, an allergoid, a peptide, a protein, a hapten, a carbohydrate, a PNA and an RNA; and

(b) an adjuvant which is magnesium carbonate hydroxide pentahydrate.

68. (New) A parenteral vaccine formulation according to claim 67 further comprising an additional adjuvant.

69. (New) A parenteral vaccine formulation according to claim 68, wherein the additional adjuvant is selected from the group consisting of a saponin, MF59, MPL, PLG, PLGA, and an aluminum salt.

70. (New) A parenteral vaccine formulation according to claim 67, further comprising a pharmaceutically acceptable excipient or carrier.

71. (New) A parenteral vaccine formulation according to claim 67, further comprising a diluent, a buffer, a suspending agent, a solubilizing agent, a pH-adjusting agent, a dispersing agent, or a colorant.

72. (New) A parenteral vaccine formulation according to claim 67, for intravenous, intramuscular, intraarticular, subcutaneous, intradermal, epicutaneous, or intraperitoneal administration.

73. (New) A parenteral vaccine formulation according to claim 67, wherein the cation of the adjuvant is present in an amount of from about 0.0004 to about 120 M.

74. (New) A parenteral vaccine formulation according to claim 67, wherein the cation of the adjuvant is present in an amount of from about 0.008 to about 6 M.

75. (New) A parenteral vaccine formulation according to claim 69, wherein the saponin is selected from the group consisting of Quil A and Qs-21.

* * * * *